Cancer risk in HIV-infected persons: influence of CD4⁺ count

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

Bibliography

• 1  Grulich AE, Tvan Leeuwen M, Falster MO, Vajdic CM: Incidence of cancers in people with HIV/AIDS compared with immunosupressed transplant recipients: a meta-analysis. Lancet370,59–67 (2007).▪▪ This large meta-analysis of population-based studies has firmly established the range of infection-related cancers that occur at excess risk in chronically immunosuppressed persons infected with HIV (PHIV) and transplant patients.
  MedlineGoogle Scholar
• 2  Frisch M, Biggar RJ, Engels EA, Goedert JJ: Association of cancer with AIDS-related immunosuppression in adults. JAMA285(13),1736–1745 (2001).
  Medline CASGoogle Scholar
• 3  Mbulaiteye SM, Biggar RJ, Goedert JJ, Engels EA: Immune deficiency and risk for malignancy among persons with AIDS. J. Acquir. Immune Defic. Syndr.32(5),527–533 (2003).
  MedlineGoogle Scholar
• 4  Dal Maso L, Franceschi S, Polesel J et al.: Risk of cancer in persons with AIDS in Italy, 1985–1998. Br. J. Cancer89(1),94–100 (2003).
  Medline CASGoogle Scholar
• 5  Franceschi S, Dal Maso L, Pezzotti P et al.: Incidence of AIDS-defining cancers after AIDS diagnosis among people with AIDS in Italy, 1986–1998. J. Acquir. Immune Defic. Syndr.34(1),84–90 (2003).
  MedlineGoogle Scholar
• 6  Biggar RJ, Chaturvedi AK, Goedert JJ, Engels EA: AIDS-related cancer and severity of immunosuppression in persons with AIDS. J. Natl Cancer Inst.99(12),962–972 (2007).▪▪ This record linkage study of persons with AIDS in the USA is the largest to date to have characterized the influence of CD4+ count at AIDS on the risk of Kaposi sarcoma (KS) and non-Hodgkin lymphoma (NHL) post-AIDS, and stratified by time periods before and after the advent of combined antiretroviral therapy (cART).
  MedlineGoogle Scholar
• 7  Engels EA, Pfeiffer RM, Goedert JJ et al.: Trends in cancer risk among people with AIDS in the United States 1980–2002. AIDS20(12),1645–1654 (2006).
  MedlineGoogle Scholar
• 8  Hermans P, Lundgren J, Sommereijns B et al.: Epidemiology of AIDS-related Kaposi’s sarcoma in Europe over 10 years. AIDS in Europe Study Group. AIDS10(8),911–917 (1996).
  Medline CASGoogle Scholar
• 9  Dal Maso L, Franceschi S, Negri E et al.: Trends of AIDS incidence in Europe and the United States. Soz. Praventivmed.40(4),239–265 (1995).
  Medline CASGoogle Scholar
• 10  Franceschi S, Dal Maso L, Rickenbach M et al.: Kaposi sarcoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. Br. J. Cancer99(5),800–804 (2008).▪▪ This prospective study of PHIV in Switzerland is a comprehensive description of how cART has drastically changed the meaning of CD4+ count as a predictor for KS onset.
  Medline CASGoogle Scholar
• 11  Mocroft A, Kirk O, Clumeck N et al.: The changing pattern of Kaposi sarcoma in patients with HIV, 1994–2003: the EuroSIDA Study. Cancer100(12),2644–2654 (2004).
  MedlineGoogle Scholar
• 12  Grulich AE, Li Y, McDonald AM et al.: Decreasing rates of Kaposi’s sarcoma and non-Hodgkin’s lymphoma in the era of potent combination anti-retroviral therapy. AIDS15(5),629–633 (2001).
  Medline CASGoogle Scholar
• 13  Engels EA, Biggar RJ, Hall HI et al.: Cancer risk in people infected with human immunodeficiency virus in the United States. Int. J. Cancer123(1),187–194 (2008).
  Medline CASGoogle Scholar
• 14  Patel P, Hanson DL, Sullivan PS et al.: Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992–2003. Ann. Intern. Med.148(10),728–736 (2008).
  MedlineGoogle Scholar
• 15  Bedimo R, Chen RY, Accortt NA et al.: Trends in AIDS-defining and non-AIDS-defining malignancies among HIV-infected patients: 1989–2002. Clin. Infect. Dis.39(9),1380–1384 (2004).
  MedlineGoogle Scholar
• 16  Gallafent JH, Buskin SE, De Turk PB, Aboulafia DM: Profile of patients with Kaposi’s sarcoma in the era of highly active antiretroviral therapy. J. Clin. Oncol.23(6),1253–1260 (2005).
  MedlineGoogle Scholar
• 17  Rezza G, Dorrucci M, Serraino D et al.: Incidence of Kaposi’s sarcoma and HHV-8 seroprevalence among homosexual men with known dates of HIV seroconversion. Italian Seroconversion Study. AIDS14(11),1647–1653 (2000).
  Medline CASGoogle Scholar
• 18  International Collaboration on HIV and Cancer: Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J. Natl Cancer Inst.92(22),1823–1830 (2000).
  MedlineGoogle Scholar
• 19  Carrieri MP, Pradier C, Piselli P et al.: Reduced incidence of Kaposi’s sarcoma and of systemic non-hodgkin’s lymphoma in HIV-infected individuals treated with highly active antiretroviral therapy. Int. J. Cancer103(1),142–144 (2003).
  Medline CASGoogle Scholar
• 20  Serraino D, Angeletti C, Carrieri MP et al.: Kaposi’s sarcoma in transplant and HIV-infected patients: an epidemiologic study in Italy and France. Transplantation80(12),1699–1704 (2005).
  MedlineGoogle Scholar
• 21  Clifford GM, Polesel J, Rickenbach M et al.: Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J. Natl Cancer Inst.97(6),425–432 (2005).
  MedlineGoogle Scholar
• 22  Martro E, Esteve A, Schulz TF et al.: Risk factors for human Herpesvirus 8 infection and AIDS-associated Kaposi’s sarcoma among men who have sex with men in a European multicentre study. Int. J. Cancer120(5),1129–1135 (2007).
  Medline CASGoogle Scholar
• 23  Nawar EW, Cole SR, Farzadegan H et al.: Sexual activity and Kaposi’s sarcoma among human immunodeficiency virus type 1 and human herpesvirus type 8-coinfected men. Ann. Epidemiol.18(7),517–521 (2008).
  MedlineGoogle Scholar
• 24  Brown EE, Whitby D, Vitale F et al.: Virologic, hematologic, and immunologic risk factors for classic Kaposi sarcoma. Cancer107(9),2282–2290 (2006).
  Medline CASGoogle Scholar
• 25  Maurer T, Ponte M, Leslie K: HIV-associated Kaposi’s sarcoma with a high CD4 count and a low viral load. N. Engl. J. Med.357(13),1352–1353 (2007).
  Medline CASGoogle Scholar
• 26  Krown SE, Lee JY, Dittmer DP: More on HIV-associated Kaposi’s sarcoma. N. Engl. J. Med.358(5),535–536 (2008).
  Medline CASGoogle Scholar
• 27  Krischer J, Rutschmann O, Hirschel B et al.: Regression of Kaposi’s sarcoma during therapy with HIV-1 protease inhibitors: a prospective pilot study. J. Am. Acad. Dermatol.38(4),594–598 (1998).
  Medline CASGoogle Scholar
• 28  El Amari EB, Toutous-Trellu L, Gayet-Ageron A et al.: Predicting the evolution of Kaposi sarcoma, in the highly active antiretroviral therapy era. AIDS22(9),1019–1028 (2008).
  Medline CASGoogle Scholar
• 29  Stebbing J, Sanitt A, Nelson M et al.: A prognostic index for AIDS-associated Kaposi’s sarcoma in the era of highly active antiretroviral therapy. Lancet367(9521),1495–1502 (2006).
  MedlineGoogle Scholar
• 30  Nasti G, Talamini R, Antinori A et al.: AIDS-related Kaposi’s Sarcoma: evaluation of potential new prognostic factors and assessment of the AIDS Clinical Trial Group Staging System in the Haart Era – the Italian Cooperative Group on AIDS and Tumors and the Italian Cohort of Patients Naive From Antiretrovirals. J. Clin. Oncol.21(15),2876–2882 (2003).
  MedlineGoogle Scholar
• 31  Dal Maso L, Franceschi S: Epidemiology of non-Hodgkin lymphomas and other haemolymphopoietic neoplasms in people with AIDS. Lancet Oncol.4(2),110–119 (2003).
  MedlineGoogle Scholar
• 32  Besson C, Goubar A, Gabarre J et al.: Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. Blood98(8),2339–2344 (2001).
  Medline CASGoogle Scholar
• 33  CASCADE: Systemic non-Hodgkin lymphoma in individuals with known dates of HIV seroconversion: incidence and predictors. AIDS18(4),673–681 (2004).
  MedlineGoogle Scholar
• 34  Kirk O, Pedersen C, Cozzi-Lepri A et al.: Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. Blood98(12),3406–3412 (2001).
  Medline CASGoogle Scholar
• 35  Polesel J, Clifford GM, Rickenbach M et al.: Non-Hodgkin lymphoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. AIDS22(2),301–306 (2008).▪▪ This prospective study of PHIV in Switzerland is a comprehensive description of how cART has drastically changed the meaning of CD4+ count as a predictor for NHL onset, especially primarybrain lymphoma.
  MedlineGoogle Scholar
• 36  Dal Maso L, Polesel J, Serraino D et al.: Pattern of cancer risk in persons with AIDS in Italy in the HAART era. Br. J. Cancer100(5),840–847 (2009).
  Medline CASGoogle Scholar
• 37  Bower M, Gazzard B, Mandalia S et al.: A prognostic index for systemic AIDS-related non-Hodgkin lymphoma treated in the era of highly active antiretroviral therapy. Ann Intern Med143(4),265–273 (2005).
  MedlineGoogle Scholar
• 38  Simcock M, Blasko M, Karrer U et al.: Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study. Antivir. Ther.12(6),931–939 (2007).
  MedlineGoogle Scholar
• 39  Newnham A, Harris J, Evans HS, Evans BG, Moller H: The risk of cancer in HIV-infected people in southeast England: a cohort study. Br. J. Cancer92(1),194–200 (2005).
  Medline CASGoogle Scholar
• 40  Herida M, Mary-Krause M, Kaphan R et al.: Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. J. Clin. Oncol.21(18),3447–3453 (2003).
  MedlineGoogle Scholar
• 41  Crum-Cianflone N, Hullsiek KH, Marconi V et al.: Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: a 20-year cohort study. AIDS23(1),41–50 (2009).
  MedlineGoogle Scholar
• 42  Fontas E, Kousignian I, Pradier C et al.: Interleukine 2 therapy does not increase the risk of Hodgkin or non-Hodgkin lymphoma in HIV-infected patients; results from FHDH ANRS CO4. J. Acquir. Immune Defic. Syndr.50(2),206–214 (2009).
  Medline CASGoogle Scholar
• 43  Clifford G, Rickenbach M, Lise M et al.: Hodgkin lymphoma in the Swiss HIV Cohort Study. Blood (2009) (Epub ahead of print).▪▪ First prospective study to describe the influence of CD4+ count on the risk of Hodgkin lymphoma onset among a cohort of PHIV.
  MedlineGoogle Scholar
• 44  Ferlay J, Bray F, Pisani P, Parkin DM: Globocan 2002: Incidence, mortality and prevalence worldwide. [cd-rom]. International Agency for Research on Cancer, Lyon, France (2004).
  Google Scholar
• 45  Biggar RJ, Jaffe ES, Goedert JJ, Chaturvedi A, Pfeiffer R, Engels EA: Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood108(12),3786–3791 (2006).
  Medline CASGoogle Scholar
• 46  Frisch M, Biggar RJ, Goedert JJ: Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J. Natl Cancer Inst.92(18),1500–1510 (2000).
  Medline CASGoogle Scholar
• 47  Galceran J, Marcos-Gragera R, Soler M et al.: Cancer incidence in AIDS patients in Catalonia, Spain. Eur. J. Cancer43(6),1085–1091 (2007).
  MedlineGoogle Scholar
• 48  Mbulaiteye SM, Katabira ET, Wabinga H et al.: Spectrum of cancers among HIV-infected persons in Africa: The Uganda AIDS-Cancer Registry Match Study. Int. J. Cancer118,985–990 (2006).
  Medline CASGoogle Scholar
• 49  Stein L, Urban MI, O’Connell D et al.: The spectrum of human immunodeficiency virus-associated cancers in a South African black population: results from a case–control study, 1995–2004. Int. J. Cancer122(10),2260–2265 (2008).
  Medline CASGoogle Scholar
• 50  Serraino D, Carrieri P, Pradier C et al.: Risk of invasive cervical cancer among women with, or at risk for, HIV infection. Int. J. Cancer82(3),334–337 (1999).
  Medline CASGoogle Scholar
• 51  Gichangi P, De Vuyst H, Estambale B et al.: HIV and cervical cancer in Kenya. Int. J. Gynaecol. Obstet.76(1),55–63 (2002).
  Medline CASGoogle Scholar
• 52  Moodley M: Reduction in prevalence of invasive cervical cancer in KwaZulu-Natal, South Africa: impact of the human immunodeficiency virus epidemic. Int. J. Gynecol. Cancer16(3),1036–1040 (2006).
  Medline CASGoogle Scholar
• 53  Minkoff H, Feldman J, DeHovitz J, Landesman S, Burk R: A longitudinal study of human papillomavirus carriage in human immunodeficiency virus-infected and human immunodeficiency virus-uninfected women. Am. J. Obstet. Gynecol.178(5),982–986 (1998).
  Medline CASGoogle Scholar
• 54  Moscicki AB, Ellenberg JH, Farhat S, Xu J: Persistence of human papillomavirus infection in HIV-infected and -uninfected adolescent girls: risk factors and differences, by phylogenetic type. J. Infect. Dis.190(1),37–45 (2004).
  MedlineGoogle Scholar
• 55  Ahdieh L, Klein RS, Burk R et al.: Prevalence, incidence, and type-specific persistence of human papillomavirus in human immunodeficiency virus (HIV)-positive and HIV-negative women. J. Infect. Dis.184(6),682–690 (2001).
  Medline CASGoogle Scholar
• 56  Koshiol J, Schroeder J, Jamieson DJ et al.: Smoking and time to clearance of human papillomavirus infection in HIV-seropositive and HIV-seronegative women. Am. J. Epidemiol.164(2),176–183 (2006).
  MedlineGoogle Scholar
• 57  Rowhani-Rahbar A, Hawes SE, Sow PS et al.: The impact of HIV status and type on the clearance of human papillomavirus infection among Senegalese women. J. Infect. Dis.196(6),887–894 (2007).
  MedlineGoogle Scholar
• 58  Safaeian M, Kiddugavu M, Gravitt PE et al.: Determinants of incidence and clearance of high-risk human papillomavirus infections in rural Rakai, Uganda. Cancer Epidemiol. Biomarkers Prev.17(6),1300–1307 (2008).
  MedlineGoogle Scholar
• 59  Chaturvedi AK, Dumestre J, Gaffga AM et al.: Prevalence of human papillomavirus genotypes in women from three clinical settings. J. Med. Virol.75(1),105–113 (2005).
  MedlineGoogle Scholar
• 60  Strickler HD, Palefsky JM, Shah KV et al.: Human papillomavirus type 16 and immune status in human immunodeficiency virus-seropositive women. J. Natl Cancer Inst.95(14),1062–1071 (2003).
  MedlineGoogle Scholar
• 61  Strickler HD, Burk RD, Fazzari M et al.: Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women. J. Natl Cancer Inst.97(8),577–586 (2005).
  MedlineGoogle Scholar
• 62  Harris TG, Burk RD, Palefsky JM et al.: Incidence of cervical squamous intraepithelial lesions associated with HIV serostatus, CD4 cell counts, and human papillomavirus test results. JAMA293(12),1471–1476 (2005).▪▪ This study of the natural history of cervical human papillomavirus (HPV) infection among women with and without HIV infection clearly establishes how declining CD4+ count worsens the outcome of a given HPV infection in terms of progression to severe cervical abnormalities.
  Medline CASGoogle Scholar
• 63  Massad LS, Ahdieh L, Benning L et al.: Evolution of cervical abnormalities among women with HIV-1: evidence from surveillance cytology in the women’s interagency HIV study. J. Acquir. Immune Defic. Syndr.27(5),432–442 (2001).
  Medline CASGoogle Scholar
• 64  Schuman P, Ohmit SE, Klein RS et al.: Longitudinal study of cervical squamous intraepithelial lesions in human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women. J. Infect. Dis.188(1),128–136 (2003).
  MedlineGoogle Scholar
• 65  Ellerbrock TV, Chiasson MA, Bush TJ et al.: Incidence of cervical squamous intraepithelial lesions in HIV-infected women. JAMA283(8),1031–1037 (2000).
  Medline CASGoogle Scholar
• 66  Hawes SE, Critchlow CW, Faye Niang MA et al.: Increased risk of high-grade cervical squamous intraepithelial lesions and invasive cervical cancer among African women with human immunodeficiency virus type 1 and 2 infections. J. Infect. Dis.188(4),555–563 (2003).
  MedlineGoogle Scholar
• 67  Hawes SE, Critchlow CW, Sow PS et al.: Incident high-grade squamous intraepithelial lesions in Senegalese women with and without human immunodeficiency virus type 1 (HIV-1) and HIV-2. J. Natl Cancer Inst.98(2),100–109 (2006).
  MedlineGoogle Scholar
• 68  Delmas MC, Larsen C, van Benthem B et al.: Cervical squamous intraepithelial lesions in HIV-infected women: prevalence, incidence and regression. European Study Group on Natural History of HIV Infection in Women. AIDS14(12),1775–1784 (2000).
  Medline CASGoogle Scholar
• 69  Paramsothy P, Jamieson DJ, Heilig CM et al.: The effect of highly active antiretroviral therapy on human papillomavirus clearance and cervical cytology. Obstet. Gynecol.113(1),26–31 (2009).
  MedlineGoogle Scholar
• 70  Minkoff H, Ahdieh L, Massad LS et al.: The effect of highly active antiretroviral therapy on cervical cytologic changes associated with oncogenic HPV among HIV-infected women. AIDS15(16),2157–2164 (2001).
  Medline CASGoogle Scholar
• 71  Massad LS, Seaberg EC, Watts DH et al.: Long-term incidence of cervical cancer in women with human immunodeficiency virus. Cancer115(3),524–530 (2009).
  MedlineGoogle Scholar
• 72  Bower M, Powles T, Newsom-Davis T et al.: HIV-associated anal cancer: has highly active antiretroviral therapy reduced the incidence or improved the outcome? J. Acquir. Immune Defic. Syndr.37(5),1563–1565 (2004).
  MedlineGoogle Scholar
• 73  Piketty C, Selinger-Leneman H, Grabar S et al.: Marked increase in the incidence of invasive anal cancer among HIV-infected patients despite treatment with combination antiretroviral therapy. AIDS22(10),1203–1211 (2008).▪▪ The first prospective study to describe the influence of CD4+ count on the risk of anal cancer onset in a cohort of PHIV.
  MedlineGoogle Scholar
• 74  Diamond C, Taylor TH, Aboumrad T, Bringman D, Anton-Culver H: Increased incidence of squamous cell anal cancer among men with AIDS in the era of highly active antiretroviral therapy. Sex. Transm. Dis.32(5),314–320 (2005).
  MedlineGoogle Scholar
• 75  Hessol NA, Pipkin S, Schwarcz S, Cress RD, Bacchetti P, Scheer S: The impact of highly active antiretroviral therapy on non-AIDS-defining cancers among adults with AIDS. Am. J. Epidemiol.165(10),1143–1153 (2007).
  MedlineGoogle Scholar
• 76  D’Souza G, Wiley DJ, Li X et al.: Incidence and epidemiology of anal cancer in the multicenter AIDS cohort study. J. Acquir. Immune Defic. Syndr.48(4),491–499 (2008).
  MedlineGoogle Scholar
• 77  De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S: Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int. J. Cancer124(7),1626–1636 (2009).
  Medline CASGoogle Scholar
• 78  Palefsky JM, Holly EA, Ralston ML, Jay N: Prevalence and risk factors for human papillomavirus infection of the anal canal in human immunodeficiency virus (HIV)-positive and HIV-negative homosexual men. J. Infect. Dis.177(2),361–367 (1998).
  Medline CASGoogle Scholar
• 79  Holly EA, Ralston ML, Darragh TM, Greenblatt RM, Jay N, Palefsky JM: Prevalence and risk factors for anal squamous intraepithelial lesions in women. J. Natl Cancer Inst.93(11),843–849 (2001).
  Medline CASGoogle Scholar
• 80  Piketty C, Darragh TM, Da Costa M et al.: High prevalence of anal human papillomavirus infection and anal cancer precursors among HIV-infected persons in the absence of anal intercourse. Ann Intern Med138(6),453–459 (2003).
  MedlineGoogle Scholar
• 81  Clifford GM, Rickenbach M, Polesel J et al.: Influence of HIV-related immunodeficiency on the risk of hepatocellular carcinoma. AIDS22(16),2135–2141 (2008).▪▪ This nested case–control study was the first to describe the influence of declining CD4+ count on the risk of hepatocellular carcinoma among PHIV, with careful controlling for factors related to co-infection with hepatitis viruses.
  Medline CASGoogle Scholar
• 82  Colin JF, Cazals-Hatem D, Loriot MA et al.: Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology29(4),1306–1310 (1999).
  Medline CASGoogle Scholar
• 83  Puoti M, Spinetti A, Ghezzi A et al.: Mortality for liver disease in patients with HIV infection: a cohort study. J. Acquir. Immune Defic. Syndr.24(3),211–217 (2000).
  Medline CASGoogle Scholar
• 84  Thio CL, Seaberg EC, Skolasky R Jr et al.: HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet360(9349),1921–1926 (2002).
  MedlineGoogle Scholar
• 85  Di Martino V, Rufat P, Boyer N et al.: The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study. Hepatology34(6),1193–1199 (2001).
  Medline CASGoogle Scholar
• 86  Graham CS, Baden LR, Yu E et al.: Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin. Infect. Dis.33(4),562–569 (2001).
  Medline CASGoogle Scholar
• 87  Kramer JR, Giordano TP, Souchek J, Richardson P, Hwang LY, El-Serag HB: The effect of HIV coinfection on the risk of cirrhosis and hepatocellular carcinoma in U.S. veterans with hepatitis C. Am. J. Gastroenterol.100(1),56–63 (2005).
  MedlineGoogle Scholar
• 88  Darby SC, Ewart DW, Giangrande PL et al.: Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors’ Organisation. Lancet350(9089),1425–1431 (1997).
  Medline CASGoogle Scholar
• 89  Rockstroh JK, Spengler U, Sudhop T et al.: Immunosuppression may lead to progression of hepatitis C virus-associated liver disease in hemophiliacs coinfected with HIV. Am. J. Gastroenterol.91(12),2563–2568 (1996).
  Medline CASGoogle Scholar
• 90  Martin-Carbonero L, Benhamou Y, Puoti M et al.: Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study. Clin. Infect. Dis.38(1),128–133 (2004).
  MedlineGoogle Scholar
• 91  Kirk GD, Merlo C, O’ Driscoll P et al.: HIV infection is associated with an increased risk for lung cancer, independent of smoking. Clin. Infect. Dis.45(1),103–110 (2007).
  MedlineGoogle Scholar